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Background: The introduction of the national electronic journal systems is considered a 
solution to provide effective and correct up to date medication information for healthcare 
professionals and contribute to minimize the potential of error. Medicine Reconciliation (MR) 
is the process of obtaining and maintaining and accurate, detailed list of all medicines taken 
by a patient and using this list anywhere within the health care system to ensure that the 
patient receives correct medicines. This thesis aimed to determine whether the electronic 
records provide a sufficient accurate patient medication record to negate the need for human 
mediated MR. 
Method: MR were conducted on patients at a Cardiologic bed ward from October 2015 until 
January 2016. MR were conducted by the IMM-method and documented medicine lists and 
discrepancies found between the hospital journal, electronic journals and a patient medication 
history interview. An expert panel consisting of two senior doctors and two pharmacists were 
asked to score the severity of the discrepancies using a validated scale. 
Results: 36 patients were included in the study where the study population had a mean (SD) 
age of 69.8(9.7) and 36.1% were female. The mean (SD) number of drugs the patients used 
were 6.97(3.03). In this study, discrepancies were found in 72,2% for both the hospital journal 
and electronic journal systems. 30 (83,3%) of the patients had at least one discrepancy in 
either the hospital journal or electronic journal systems. For the hospital journals the mean 
number of discrepancies per list were 2,58, and 2,73 for the electronic journal systems.  
Conclusion: There was no evidence of the impact of electronic journal systems on the 
medicine lists to negate the need for human intervention, and the existing process of care 
transition communication at the healthcare interface is not optimum. Evidence to support the 
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ATC: Anatomical Therapeutic Chemical 
IMM: Integrated Medicines Management 
PS: Prescription Supplier 
SCR: Summary Care Record 
MR: Medicine Reconciliation 
GP: General Practitioner 
NICE: National Institute for Health and Care Excellence 
NPC: National Prescribing Centre 
SD:  Standard Deviation 
US/USA: United States of America 
UK: United Kingdom 














Glossary terms used in this thesis 
GP:  The doctor who practice in a primary care environment (primary care 
practice) 
ATC-system: Classification system of drugs that categorise in all drugs in groups of 
five levels from which organ they affect (level 1) to their active 
substance (level 5) 
PRN-drugs: Drugs that the patient only use when needed 
Compliance: The degree to which a patient correctly follows medical advice 
Adherence:  The extent to which a patient continues an agreed-on mode of 
treatment without close supervision 
Intervention: An act to change or improve  
Medical curve: List of the drugs/medication that the patient receives at the hospital, 
including an overview of drugs at admission 
Primary Care: The team of GPs and staff such as practice nurse, practice 
pharmacists, and receptionist who provide primary health care  
Secondary Care: The health service provided by medical specialists who generally do  
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1.1 Medication errors and consequences 
Medication usage in Norway has increased by 15% the last 10 years and is the primary 
healthcare intervention used in western society(1). The total sale of medication in Norway 
increased in 2014 with 8,9 % from 2013, while 43 % of the population in 2012 got medicines 
on blue prescription(1). Medication therapy is an essential part of today’s healthcare. 
According to the Norwegian Institute of Public Health, 69% of the population in Norway 
collected at least one drug on prescription in 2013(1). Even though drugs may improve health 
and reduce morbidity, it may also arise complications in connection to drug use. This is 
commonly referred to as medication errors or adverse drug events, and may be of harm to the 
patient and a threat to the patient safety. 
The American US Food and Drug administration defines medication errors as “Any 
preventable event that may cause or lead to inappropriate medication use or patient harm 
while the medication is in control of the health care professional, patient or consumer. Such 
events may be related to professional practice, health care products, procedures, and systems, 
including prescribing; order communication; product labeling, packaging, and 
nomenclature; compounding; dispensing; distribution; administration; education; 
monitoring; and use.”(2). This definition is broad and includes errors from when the drug is 
produced until it is taken by the patient. Adverse drug events (ADEs) are defined as “an 
injury resulting from the use of a drug. Under this definition, the term ADE includes harm 
caused by the drug (adverse drug reactions and overdoses) and harm from the use of the drug 
(including dose reductions and discontinuations and overdoses)”(3). So even though ADEs 
results from the use of drugs, it does not have to be a result of medication errors. 
A study in Norwegian Hospitals identified that 80 % of all patients had an average of 2,1 
relevant adverse drug problems, and therefore managing the way that medicines are 
prescribed and administered to patient is of concern to patient safety(4). 
Between 2008-2011, the Norwegian Board of Health Supervision registered 7756 reports 
about unwanted events, whereas 14% of these was related to adverse drug use(5). Adverse 
drug use are the cause of 12% of all patient harm and it was reported that at least 1000 
patients die every year caused and related to side effects and adverse drug use(6). Noting that 
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the Centre for reporting relies on health personnel reporting errors, it is likely that the 
numbers are potentially underestimated and therefore poses a larger health challenge.  
In Norway, the Directorate of Health reported that 5 % of acute hospitalizations is caused by 
side effects and adverse medicine use, and that half of these events and hospitalizations could 
have been avoided if the medicines management was improved(7). It is estimated that adverse 
or unfortunate medicine use increases 490 000 additional bed-days and 2 billion NOK every 
year(8).  
Every seventh elderly patient are rehospitalised in Norwegian Hospitals within 30 days, and 
the Health Departments statistics show that total number of hospitalisations in Norway 
increased by 260 % from 2011-2014 from 23 969 to 84 269 hospital stays for discharge ready 
patients(9). These are patients that can either be taken care of the Municipal Health Care 
System or have received therapy and treatment that can be continued by the primary health 
care. The average length of stay for discharge ready patients has since 2011 been halved from 
14,1 days to 7,6 in 2014, and the increased transition of patients between primary and 
secondary care provides an increased opportunity for medication errors(9). 
As a result of the increased use of medicines, number of hospitalizations and number of 














1.2 Definition of medicine reconciliation 
In response to concerns about patient safety at health transitions medicine reconciliation (MR) 
was proposed as a solution from the Institute for Healthcare Improvement(10). The definition 
of MR varies among health professionals, but the Joint Commission, which is an USA based 
non-profit organization that accredits health care organizations, defines the MR as the process 
of comparing the patients’ medication orders to all of the medicines that the patient has been 
taking. The process should be performed at every transition of care which includes changes in 
setting, service, practitioner or level of care. According to the Joint Commission the MR 
process involves five steps. The first is to develop a list of current medicines, then develop a 
list of medicines to be prescribed, compare the two lists, make clinical decisions based on the 
comparison and lastly communicate the new list to the next care provider and to the patient. 
The Institute of Healthcare Improvement describes three steps for the MR process as 
summarised in BOX 1.1, verification, clarification and reconciliation. 
BOX 1.1 MR Steps defined by the institute of healthcare improvement 
 Verification 
The first step involves collection of medication histories 
 Clarification 
Secondly, ensure that medicines and doses are appropriate 
 Reconciliation 
Thirdly, document all changes in inpatient medicine orders or charts 
The process starts when the patient is admitted to the hospital, continues whenever 
the patient is transferred to a different level of care, and occurs again when the 
patient is discharged from the hospital. 
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The UK National Prescribing Centre (NPC) developed a similar definition and describes MR 
in two stages, whereas the main steps are collecting, checking and communication. The MR 
process as described by the the NPC is presented in BOX 1.2. 
The NPC adopts the 3C approach including the two stages in three steps: collecting, checking 
and communication. The collecting step involves taking a medication history and collecting 
other relevant information about the patients’ medicines that can be collected from a range of 
different sources. The medication history should be collected from the most recent and 
reliable source. Where it is possible, the information should be verified and cross-checked 
with multiple sources. Where there appears to be discrepancy between what the patient is 
currently prescribed and what the patient is actually taking, it should be recorded, and where 
they can be established, the reasons for any variation. The checking step involves ensuring 
that the medicines and doses that are now prescribed for the patient are correct, and lastly the 
step to communicate where any changes that have been made to the patients’ prescription are 
documented to the next care provider. 
In 2011 the Norwegian Ministry of Health and Care Services initiated a national patient safety 
program “In Safe Hands 24/7” that would implement intervention on certain areas in the 
specialist- and primary health care(11). The purpose of the intervention in the campaign is to 
point at specific areas where there is improvement potential to reduce patient harm in the 
health care, build a long lasting structure for patient safety and to develop a respectable 
patient safety culture in the health care(11). Medicine Reconciliation is one of these 
intervention areas, and the campaign has developed a Norwegian definition of MR based on 
the definition of the World Health Organization (WHO) whereas it states that “Medicines 
BOX 1.2 NPC Medicines Reconciliation Process 
 Basic Reconciliation (stage 1) 
Basic reconciliation involves the collection and accurate identification of a patient 
current list of medicines. An example would include medication history-taking in 
secondary care upon admission) 
 Full Reconciliation (stage 2) 
Full reconciliation involves taking the basic reconciliation information and 
comparing it to the list of medicines that was most recently available for the patient. 
In addition to that, it involves identifying any discrepancies between the lists and 
then acting on that information accordingly. 
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Reconciliation is a method that health personnel in cooperation with the patient shall secure 
transfer of correct information about the patients actual medicine use”(12).  
Pharmacy led MR has been implemented at different point of care, including admission 
MR(13-15) or discharge MR alone(16-18). In fewer number of studies full MR process was 
implemented as in both admission and discharge(19-21). MR was mostly led by a pharmacist 
with clinical training; however, less frequently MR was implemented by pharmacy 
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1.3 Integrated medicines management 
The Hospital Pharmacies in Norway implemented the Integrated Medicines Management 
(IMM) method in 2013 with the expectation of good and secure drug therapy for hospitalized 
patients and correct transfer of information of the patients medicine use when changing level 
of care. The Integrated Medicines Management (IMM) is a method of standardising the MR 
approach and consists of three phases, the first one being medicines reconciliation, then 
medication review and lastly consultation and documentation of changes. The process entails 
comprehensive pharmacy teams involved at admission, inpatient stay and at discharge, 
incorporating communication at the transitions where most medicine-related problems occur. 
Scullin et al. sets evidence to supports its use and describes the method thoroughly in the 
article “An innovative approach to integrated medicines management”(27).  
 
 
Figure 1-1 The pharmacists work process using Integrated Medicines Management (IMM) in 
hospitals 
1.3.1 Medication history at admission 
The first part of the IMM-method is gathering of the patients accurate medication history 
shortly after admission by the pharmacist. Firstly, collection of a drug list from the hospital is 
used as a starting point and afterwards, an interview with the patient where information on 
conditions and drug use is collected. The construction of an accurate and precise as possible 
drug list is then accomplished using several sources, for example the pharmacy, GP, 













also registered. Discrepancies and details on the patients drug use is then compared to the 
drugs prescribed in hospital and discussed with responsible doctor. 
1.3.2 Medication review under hospital stay and consultation at discharge 
The second part of the IMM-method is a pharmacist review of the patients drug list and 
assessing if the treatment is optimised. The pharmacist evaluate if the conditions are properly 
treated and also in consideration of laboratory tests. The evaluation of the treatment is then 
discussed with the responsible doctor. Before the patient is discharged from the hospital, the 
pharmacist undertakes a consultation with the patient giving information on new drugs if any 
and the changes in treatment that has been done. The patient also receives information 
material on their drugs and the updated drug list. The list is also sent to the GP and the 
pharmacy. 
In Sweden, this model is further developed to the LIMM-method (Lund Integrated Medicines 
Management) and adapted to Swedish conditions. LIMM has its own procedures and tools to 
perform the MR, whilst in Norway The Hospital Pharmacies of Mid-Norway has 
implemented “IMM in Mid-Norway” and is still under development of procedures and tools. 
The aim of these methods is to increase the quality and flow of drug information between 














1.4 Medicine Reconciliation in Norway 
Successive reports from the Norwegian government in 2005 and 2012 have identified that 
adverse drug events, whereby medicines have been used incorrectly or found to be ineffective 
are the cause for 5-10% of all hospitalizations in medical wards. This can be extrapolated 
nationally to 5 billion NOK every year(6, 28). In addition to this, in 2013 19% of all reports 
sent in regarding considerable patient harm from the secondary care were related to medicine 
use. A government report from 2014-2015 states that the main reason for adverse drug events 
(ADE) is a lacking overview of the patients’ medicine use, incorrect prescribing by the doctor 
or that patients does not receive adequate supervision and guidance on their medicine use(6). 
The government report states that medicines related harm can often be explained by 
insufficient training of health care personnel, inadequate routines, imprecise distribution of 
responsibility and poor transfer of information when patients transfer between care 
settings(28). Because of the amount of ADEs, incorrect use of medicines and number of 
hospitalizations and errors, it has become necessary to identify areas for improvement in the 
current practice of pharmaceutical care. 
There are two main transfer points where errors can be introduced, one is on admission to 
hospital and the other is upon discharge from secondary care to primary care. Traditionally, 
nurses or junior doctors who both have limited experience and knowledge of medicines obtain 
information upon admission and are responsible for collecting the patients’ medication history 
(13, 29). Moreover, patients access emergency departments with injuries or illnesses 
frequently out of hours, making the amount and quality of information less predictable(30). 
The quality of discharge information can depend on the quality of admission information, 
meaning if errors were introduced at the admission stage they are likely to follow upon 
discharge(31, 32). 
Several numbers of studies and reports highlight that information on admission and discharge 
is often incomplete and inaccurate. 
A national supervision report from the Norwegian Board of Health Supervision in 2016 found 
insufficiencies in the care when the patient was discharged from the hospital(33). The report 
revealed that patients were given too little information about the treatment, but also presented 
severe errors in information transfer between the hospital and community care. Transfer of 
information was the area that the report found most errors and areas for improvement, in both  
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Author Location Year Study Design Sample 
Size 
% DRPs 
Blix HS  Oslo, Norway 2004 Prospective 827 81 % 
Viktil Oslo, Norway 2006 Prospective 96 4.4 DRP per 
patient 
Davidsson Oslo, Norway 2011 Prospective 93 88 % 
Willoch Oslo, Norway 2012 Randomized 
controlled 
77 4.3 DRP per 
patient 
      






Holmestad 4 hospitals, 
Northern, 
Norway 
2015 Prospective 249 59% 2,4 
Halbostad Namsos, 
Norway 









2015 Prospective 120 94,2% 4,1 
Wilhelm Surgical and 
ortopedic 
ward, Førde 




























2012 Prospective 50 84 % 3,5 




content and process of delivering information. In one of the hospitals, the board found that 18 
of 19 journals was not sent epicrisis/discharge notes to the GP or homecare. 
In 2012 Lao et al. undertook a prospective observational study in an infection medical ward in 
Norway whereas the objective was to research to which extent the patients’ medicine list at 
admission is accurate compared to what the patient was actually using(34). The study used a 
part of the Integrated Medicines Management model to record medication history and the 
pharmacist performed a standardized retrieval of medicine information of patients who before 
admission managed their own medicine. Clinical relevance of the discrepancies were also 
assessed, but the method was not validated and was prepared by a project group consisting of 
a physician and pharmacist. 53 patients were included, whereas 87 discrepancies were 
recorded, 2.7 per patient of the ones that had discrepancies. The most common discrepancies 
were recorded as “missing in medication list” and “error in dosage”. Additionally, 28% of the 
discrepancies were considered as moderate, very or particularly clinical relevant. 
In 2011 Frydenberg et al. concluded after a study at a medical ward in Gjøvik, Norway that 
information on patient medicines are often inaccurate in transitions between care settings and 
that the majority of errors were made when the patients were admitted to hospital. 50 
discrepancies were found among 30 patients and it was found frequent discrepancies between 
what is actually taken and documented on the hospital journals and records(35). 
Engnes et al. reviewed 120 patients medical charts in a general medical ward at Ullevaal 
University Hospital, Norway documenting at least one discrepancy in 94,2% of the 
patients(36). 208 medicines were identified as regular medicines used by the patient, but not 
documented on the patient admission list. Similar, a study at the University Hospital of 
Northern Norway highlighted the need for better medication histories as 84% of the 
medication charts they reviewed contained a discrepancy(37). These findings from Norwegian 
studies are of note and suggests that there is a need for improved medicines related processes 
at transfer of information; however they are mostly of small size with methodological 
limitations. There are no large scale evalutations of the quality of information transferred at 
the health interfaces. 
In 2011 the Ministry of Health and Care Services completed the previously mentioned patient 
safety campaign as a result of the evidence on increased adverse events leading to patient 
harm, including adverse drug events and the aim were “to reduce patient harm, build 
permanent structures for patient safety and improve the patient safety culture in the health 
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care”. The campaign was extended in 2013 to a patient safety program with the same name, a 
five-year project that through various actions had the same purpose in strengthening the 
patient safety(38). The program selecteded a few special areas of priority to improve where 
the program would introduce concrete new care. Areas were chosen on the basis that they 
have a real potential for improvement, documentation for positive effects and the ability to 
measure the impact of new care(38, 39). 
Medicines Reconciliation(MR), which is defined as the process of securing transfer of correct 
information about the patients actual medicine use, was chosen because of the challenges in 
accurate use of medicines(40). The patient safety program highlights the increasing amount of 
adverse drug events related to medicine use leading to patient harm as the main concern, and 
also states that incomplete medication information leads to inadequate and incorrect care for 
the patient. The program has facilitated for implementing MR by producing a package that 
intend to lead to enhanced procedures mainly aimed at hospitals and GPs. The actions consist 
of  
1) GPs must reconcile, update and dispense a medicine list to all patients 
2) In hospitals, medication history must be obtained, recorded and monitored at 
admission 
3) A updated and reconciled medicine list must be included in the discharge letter 
4) The patient must obtain a reconciled and updated list at discharge from hospital and in 
outpatient consultations where treatment is changed 
Apart from this, the program does not propose a clear guidance to how MR at the hospitals 
should be accomplished. The regional health authorities must therefore implement their own 
procedures for MR at their hospitals. In addition to the program, the need for mapping of 
reconciliation with optimized quality was further enhanced by the changes in law regulations 
from the 1st of January 2015 regarding medicines management(41). The law require the health 
region departments to “ensure that the internal control systems has procedures that assure the 
quality of the information about the patients medicine use on admission, discharge and when 
transitioning internal at the hospitals”.  
In response to the patient safety program and change in law regulations, there has been 
growing evidence on MR processes in Norway. In 2012, Willoch et al. researched in a 
rehabilitation ward at a general hospital whether the inclusion of pharmacists in the team 
reduced the number of drug-related problems (DRPs) in the ward and whether an intervention 
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affected the drug use after discharge(42). DRPs are defined as an event or circumstance that 
are connected with drug therapy and can actually or potentially interfere with wanted health 
effect. Potentially interfering meaning as in circumstances that might cause drug related 
morbidity or death if not acted upon, while an actually problem is defined as an adverse drug 
event already establishing with symptoms. 40 patients were randomized into an intervention 
group (IG) and 37 to a usual care group (CG). A clinical pharmacist reviewed their drug 
therapies using information available from medical records and interviews, and followed the 
patients in the IG group prospectively during their hospital stay. Drug-related problems were, 
if established by the clinical pharmacist, discussed with multidisciplinary teams led by 
physicians, and additionally the pharmacist also provided patient counselling before 
discharge. In the intervention arm, a clinical pharmacist was part of the multidisciplinary 
team, whilst usual care patients received their service from a team where a clinical pharmacist 
were not part of the treatment teams. At admission 4.4 drug related problems (DRPs) per 
patient were recorded in the IG and 4.2 DRPs per patient in the CG group. Significantly more 
DRPs were acted upon and resolved in the IG; at discharge, the IG had 1.2 DRPs per patient 
compared to 4.0 per patient in the CG (P < 0.01). The study suggests, even though it had a 
small sample size, that the involvement of pharmacists in drug therapy management improved 
the identification and resolution of drug related problems. However, DRPs are an outcome 
measure that does not define the end results for the patient and may over emphasize the 
effectiveness of the intervention as many DRPs may be more theoretical than actual, and 
many of those which are not theoretical may have limited clinical impact. The study does also 
not describe benefits for the patient on readmissions, length of hospitalization or hospital 
visits.  
In 2012 the Surgical Ward at Ålesund Hospital in Norway, implemented medicines 
reconciliation at bed units as intervention towards reducing medication errors and 
discrepancies. A prospective controlled study which aimed to research the effect of this 
implementation was performed(43). Nurses, who were also assisted by a pharmacist with 
feedback performed the medicine reconciliation, and were ultimately responsible for 
gathering medication history from patients and other relevant information sources such as 
discharge letter, pharmacy etc. 191 patients were recruited to the study, 77 in the control 
group and 114 in the intervention group. For the control group there was found 93 
discrepancies among the 77 patients (1.21 per patient) and 51 discrepancies in the 114 patients 
in the intervention group (0.45 per patient). The amount of patients with at least 1 discrepancy 
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were reduced from 52,0% to 25.4%. It was though only possible to complete a medication 
history interview with 60 patients (77,9%) in the control and 74 patients (64,9%) in the 
intervention group. For patients who did not go through an interview, the medication history 
were supplemented with written information from GP, home care service, multidose list 
and/or interview with next of kin/relative. These are all information sources that does not 
provide the information the same quality in what the patients actual medicine use is, and the 
amount of discrepancies may have been further reduced according to the trend if an increased 
amount of patients went through an interview.  
The nurses in the study at Ålesund Hospital received 1 hour of training, which is of limited 
amount of time and may have led to inadequate reconciliations. A qualitative study at the 
same hospital also showed that nurses believe that pharmacists are better qualified at 
performing medicines reconciliation(44). This agrees with a prospective cohort study in the 
UK that compared inpatient medication histories across disciplines, as pharmacists were 
showed to correct significantly more discrepancies and result in more accurate medication 
histories and reconciliation(45). A randomized controlled study in the University Hospital of 
Northern Norway (UNN) 2012 showed though no significant difference in the amount of 
discrepancies recorded by pharmacists and nurse, but showed that pharmacists used 30% less 
time than nurses and treating doctor also agreed significantly more often with the pharmacist 
in discrepancies recorded(46). This suggests that in clinical situations, discrepancies recorded 
from a pharmacist are considered more clinically relevant. 
A similar study to Holler et al. at Ålesund Hospital was conducted at the hospitals of Helse 
Nord HF (The Regional Health Department in North) by Holmestad et al. Helse Nord was 
allocated financing in 2013 to implement a medicines reconciliation process intervention to 
increase the quality of medicines information and the patient safety. Holmestad et al. 
performed a study to measure character discrepancies at four hospitals in Helse Nord, 
research what factors that leads to discrepancies, and additionally study the relationship 
between MR and discrepancies identified(47). 249 patients were included in the study, where 
54% of the patients included went through a MR process by pharmacists, that were trained in 
the Integrated Medicines Management(IMM) method beforehand performing the study. 
Holmestad et al. identified that 59% of the patients had a discrepancy in their medicine list, 
mean discrepancy on 2.4 per patient, a result that is lower than the study at UNN by Aag et al.  
A trend for reduced discrepancies in medicine lists that had documented MR was observed, 
but the result was not significant, as reconciled lists after the procedure did not seem to affect 
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the amount of discrepancies. This is in contrast to the results from Viktil et al. that included 
720 patients in four hospitals in Norway 2006(48). Clinical pharmacists assessed drug related 
problems (DRPs) by reviewing medical records and conducting interviews and by 
participating in multidisciplinary team discussions. 96 patients were randomly included for 
intervention as significantly more DRPs in the interview group, a mean 4.4 DRPs vs 2.4 
DRPs in the non-interview group, was found. Of a total 431 DRPs recorded, 168 were 
disclosed through the interviews. The low number of patients in the intervention group might 
suggest that there are practical barriers in implementing an MR process. 
To improve implementation and intervention, enhanced strategies than those in Holler et al., 
Holmestad et al. and Viktil et al. might lead to improvements in medication history recording. 
Lea et al. in 2015 investigated the effect of teaching and checklist implementation on 
accuracy of medication history recording at admission(49). The study involved two periods, 
where the first period P1 comprised non-mandatory teaching lessons for physicians and 
nurses at the ward and the emergency department. A medically responsible physician and a 
clinical pharmacist held the teaching lessons, whereas the focus lay on results of medicine 
reconciliation and possible consequences of an inaccurate medication history recording. In the 
second period P2, a checklist was implemented beforehand at the emergency department to 
facilitate the registration of medication information during admission and transition. Two 
clinical pharmacists performed the medication history interview. 56 patients and 119 patients 
were included respectively in P1 and P2. 133 discrepancies were revealed in P1 and 221 in 
P2, but there was not found any statistical significant difference in proportions of patients 
with a minimum of one discrepancy. For 60 of 119 patients (50.4%) in P2, the checklist was 
used, however, only in 8 patients (6.7%) were the checklist used during the whole stay. The 
checklist were exclusively used for 40% of the patients at the emergency admission and 
exclusively for 5% at the ward. The lacking effect and little impact may have several 
explanations, but an obvious reason was the very restricted use of the checklist. As the 
teaching lessons were non-mandatory, the participation rate and therefore knowledge of the 
intervention was limited. 
Damlien et al. conducted another study aiming to develop a prioritizing model for conducting 
MR at a fast-paced workflow emergency department (ED) and implementing an efficient 
working model for MR in 2015(50). The study included a total of 276 patients at 
Diakonhjemmet Hospital, Norway, as medication discrepancies between hospital admission 
records and information on prehospital medication use were recorded. A multidisciplinary 
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panel assessed clinically relevant medication discrepancies (crMDs) as a survey among the 
physicians made up the basis for the model of conducting MR. Clinical pharmacists or trained 
nurses performed MR, and the results showed that 62% of the patients had at least one crMD. 
The model developed from the study presented risk factors as sex (woman), age (>60), one or 
more admissions to hospital in the last 12 months and admission causes as surgical, 
malfunction or cancer were suitable for prioritization. The model classified 76.1% of the 
patients as high risk patients for having a crMD. 
The literature presented displays that MR is a developing place for evidence and suggests that 
it might improve care transition and patient outcomes. A mini review by Viktil et al. also 
emphasizes the increasing evidence of clinical pharmacists, but also highlights the need for 
studies with larger populations, including patients from multiple sites(51). Evidence is needed 
to draw conclusions as studies in Norway are of very limited number, non-randomization, 
small sample size, based on less rigorous designs and varied very in intervention and 
outcome. Additionally, none of the studies seems to describe and measure the benefits for the 
patients and therefore there is no clarity about the true effects of pharmacy led MR on ADEs 
and clinically significant errors. DRPs are a common outcome measure used in Norwegian 
studies, but the measure is a proxy and does not describe the end benefits for the patient, or 
how the intervention actually affects the quality of life and their health outcomes. It would be 
better to measure actual patient outcomes as DRPs includes the potential circumstances that 
might cause harm and varies in extent and consequences. In other words, it means that it does 
not define the patients’ health status, and therefore using DRPs as a measure might inflate the 
issues of drug therapy problems and process measure of potential harm rather than measure of 
actual clinical harm. The recommendations are also of limited generalizability due to 
differences between the studies and there are no studies describing the cost-effectiveness of 
interventions or the effect on adverse drug use and health resource use.  
The Hospital Pharmacies are ultimately responsible in teaching and training their pharmacists 
in the Integrated Medicines Management (IMM) method through courses and lessons. Nurses 
are in Norway though considered an integral part of the MR process by means of that they are 
in close to patient care and naturally in a position to collect medication history. However, it 
seems that healthcare professionals may resist in existing practice, due to time and/or 
workload concern and importantly insufficient training or education of the process. 
Additionally, there is no clear agreement about the profession responsible for implementing 
MR across settings. As the government and Parliamentary Reports focuses on MR and 
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pharmacist intervention as a potential service to improve patient safety and is one of the 
focused areas in the patient safety program, this highlights the need for further relevant 
evidence in Norway on the effect, cost-effectiveness, implementation process and education. 
 
1.5 International studies; Benefits, effects and outcome of medicine reconciliation 
MR has been evaluated across various settings such as ambulatory care(52, 53), emergency 
department(54-56), surgical pre-admission clinic(20, 57) and outpatient(58). The MR process 
has also been supplemented with other clinical activities such as discharge counselling(23, 59-
61), patient education(24, 56, 62), medication review(23, 27, 56, 63, 64), participation with 
ward rounds(13, 65), adherence aids(18) and telephone follow up(21, 24, 26, 62). A number 
of studies have evaluated the pharmacist role in medication history taking and shown 
improvement in the accuracy of medication histories, inpatient charts, discharge prescription 
and allergy information. Some of these studies are however, of small size, uncontrolled 
observational and of before and after design(13, 54, 65-68). Therefore, conclusions have most 
likely been biased in favour of the pharmacist intervention. 
A USA study in 2012 consisted of 102 patients who received pharmacy led MR compared to 
116 patients who received MR by the doctor. The MR pharmacist enhanced completeness of 
medication history and reduced adverse drug events attributed to admission errors(69). This 
agrees with a previous USA study in which a pharmacist or pharmacy student led the 
reconciliation who obtained medication histories(70). These two studies used a non-random 
selection of patients admitted to general medical units, and the findings are consistent with a 
Canadian study across surgical pre-admission assessment, which adopted a randomized 
control design. The study had 227 patients randomized into the intervention group and 237 in 
the control group, and compared pharmacy led MR with nurse-conducted medication histories 
plus surgeon-generated discharge summaries. In the intervention group, 20,3% had at least 
one postoperative error related to home medications, compared to 40,2% of the control group. 
In addition, 29,9% of the patients in the control group had at least one medication discrepancy 
postoperative which had the potential to cause possible harm compared to 12,9% in the 
intervention group(57).  
A study in Northern Ireland, Scullin et al. 2007, included 371 patients in the intervention 
group and 391 in the control group. The intervention significantly lowered readmission rates 
over 12 months by 10%, and also delayed the time of readmission as intervention patients 
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took on average 20 days longer to be readmitted than patients in the control group(27). A 
recent Swedish study conducted by Gillespie et al. evaluated readmissions and emergency 
department visits combined for 199 patients randomized in the intervention group and 201 
patients to the control group. The patients in the intervention group showed a significant 
reduction in readmissions and emergency department visits compared to control patients(71). 
Both of these two randomized controlled studies showed significantly fewer readmissions and 
emergency department visits for patients receiving pharmacy led MR compared to standard 
care, and evaluated the effect of full MR process at both admission and discharge compared to 
absence of MR at the control group. Scullin et al. also showed a significant reduction in stay.  
French studies, Leguelinel-Blache et al. showed that MR, where a clinical pharmacist 
obtained a correct list of medications before the doctor prescribed medicines on the hospital 
reduced the number of lists with discrepancies from 46% to 2%(72). Curatolo et al. examined 
the impact of implementing and sustaining a MR process at admission in two surgery units on 
unintended medication discrepancies with close-collaboration between pharmacy and surgery 
units. Before implementation mean unintended medication discrepancies (UMDs) per patient 
was 0,65 at admission. After two cycles of optimization of the procedure, UMDs per patient 
was reduced to 0,15(73). 
Two recent systematic reviews of hospital based MR conducted by Mueller et al.(74) and 
Kwan et al.(75) identified that the most successful interventions relied on pharmacists and 
outlined that MR appears to be a potentially promising intervention to improve transition. 
Both reviews on hospital based MR supported pharmacy led interventions. Mueller et al. 
found a consistent reduction in medication discrepancies, meanwhile Kwan et al. found no 
effect of MR on reducing discrepancies, which were considered clinically significant, but a 
significant reduction in emergency department visits and readmissions were identified at post 
discharge. Kwan et al. presumed the observed difference resulted from methodological 
differences between the two reviews, mainly in the selection criteria.  
In the UK medicines reconciliation is required as a service delivery in the medicines 
management process. The NICE guidance in 2007 implemented a recommended pharmacist 
involvement in MR at admission based on findings from one randomized controlled trial, two 
before and after and five observational studies presented in a systematic review conducted by 
the university of Sheffield(76). This described the effect and cost-effectiveness of 
interventions aimed at preventing errors upon admission. Pharmacy led MR appeared to be 
beneficial in reducing medication discrepancies and additionally provided evidence that some 
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form of intervention to improve medicines reconciliation is a cost effective use of resources. 
The guidelines recommend that MR is carried out by a trained and competent health 
professional – ideally a pharmacist, pharmacy technician, nurse or doctor with necessary 
knowledge, skills and expertise within 24 hours or sooner in an acute setting if clinically 
























1.6 Impact of e-records and systems 
1.6.1 IT based information transfer initiatives 
Implementing computerized IT is considered a solution to ensure effective and correct 
communication at health interfaces. It is well accepted that employing an electronic pro-forma 
has enhanced legibility of discharge summaries(18, 77). However, the risk of user selection 
and human errors is increasingly being reported(78, 79). In addition to IT based solutions and 
transfer of information, the use of IT applications to integrate MR with medicine entry orders 
and medicine management software might hold potential for further enhancing patient safety 
as healthcare decision makers should not rely solely in technology to improve patient care. 
In Canada in 2007 a web-based application implemented enabled general practitioners (GPs) 
to see information regarding their patients’ emergency department visits for 2022 visits. The 
feedback was that GPs found the information more useful, they could manage patients better 
and initiated actions more often following the information. Even though those points could 
point to the benefit on ensuring accurate and continued care, they were not reflected in a 
reduction in GP visits after discharge(80). Similarly, the use of a computerized MR tool 
integrating medicines list from several electronical sources enabled health personnel to review 
medicines reported to decrease unintentional discrepancies which were considered of 
potential harm. The benefits were nevertheless not apparent on readmissions and emergency 
department visits.  
In the US, Platte et al. in 2010 undertook a study to determine the accuracy of patients’ 
electronical medical records (EMR) drug profiles. The study evaluated the EMR of 200 
patients, whereas only 56% had accurate drug profiles and discovered that infrastructure 
improvements by themselves are fallible, and should be complemented with improvements 
such as a MR program(81). Ekedahl et al. studied discrepancies between data in the 
medication list (ML) in the EMR and data in the prescription list (PL) stored in the national 
prescription repository in Sweden, to determine current, noncurrent, duplicate and missing 
prescriptions. 66 patients were included in the study and more than 80% of the patients had at 
least one discrepancy, a noncurrent, duplicate or a missing prescription in the ML and PL(82). 
The overall congruence for unique prescriptions on current treatment between the ML and PL 
was estimated to only 55%.  
In 2007 the UK patient safety advisory committee observed that the evidence is insufficient to 
make recommendations on the use of IT based applications(83).  Since then, multiple new and 
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developing solutions and applications have appeared to have benefits on reducing medicine 
errors and improving accuracy and usefulness of communication(80, 84). It is, however not 
established if these improve healthcare resources, and IT application features and the 
advances with the technology would widely vary between settings. This would make it hard to 
apply their applicability on implementations on a wider scale. 
 
1.6.2 Electronical records and IT initiatives in Norway 
The Norwegian Parliamentary Report nr. 47 from 2008-2009 describes a common real-time 
overview across clinicians and settings of care as a solution to information challenges(85). 
The aim is to make health information available to health professionals when they have an 
official need regardless of where the patient was previously treated. In addition, the 
government wishes for citizens to have access to their own data and that data should be 
available for quality improvement, health analysis, management and research. A better and 
more complete overview gives a better knowledge and decision making basis for health care 
professionals and patients for further treatment.  
In February 2013 the Prescription Supplier (PS), an electronic database for prescriptions was 
implemented nationally for GPs, private specialists and emergency hospitals(86). This means 
that medicines prescribed by the doctor are saved in a central database whereas pharmacies all 
over the country can open and dispatch the prescriptions. The expectations for the supplier 
were that it would provide an accurate and up to date medication list for access by all 
healthcare professionals and contribute to minimize the potential of error as it reduces the risk 
of medication errors caused by a lack of overview.  
The Summary Care Record(SCR), another national electronic database was introduced in 
2014-2015 and the record gathers selected important and critical information on patients’ 
health, including drugs prescribed by a doctor and dispatched drugs from the pharmacy and 
makes them available for health care personnel and the patient themselves(87). The SCR is a 
service in addition to the medical records held by the GPs, out-of-hours services and 
hospitals. The current solutions for e-prescription has contributed to better communication 






Figure 1.2 Diagram of chain of electronic information transfer 
The SCR and PR are linked and therefore synchronized with each other (figure 1.1) The PS 
are also linked to the electronic systems to the pharmacies and to My Prescriptions which is a 
website for the patients containing information on their e-prescriptions. Whenever a 
prescription is dispatched from the pharmacy, a notification is sent to the PS, which again 
synchronizes with the SCR and My Prescription. In addition to this, the doctors’ systems can 
also look into the PS, recall and set new prescriptions for the patient.  
The evidence presented earlier (impact of e-records and systems) suggests though that 
electronic records has its limitations by involving a risk of human errors and user selection. 
Additionally, changes may be made which don’t translate onto the electronic record and the 
records/databases does not provide direct information about the patients’ actual medicine use, 
it only provides information of which medicines that has been dispatched to the patient 
without giving information on adherence. There is also a limit to historical data on the records 
as it does not provide information about non-valid prescriptions that may have been called 
back because of side effects, allergies or for other reasons and additionally there is no 
information on drugs bought over the counter (OTC). Thus, IT based solutions holding a 







2. Thesis purpose 
Most of the studies on MR in Norway are conducted before or in between the transition from 
paper to electronic journals. The implementation of the e-records is a process and health care 
professionals must adapt to new practice, thus most studies is performed without the aspect of 
new IT based solutions. 
The increased use of medicines, hospitalizations and errors previously mentioned shows the 
necessity of intervention for improvement and the evidence from international studies 
supports the impact of a MR intervention in cost-effectiveness and reducing stay, errors and 
possible harm. There is also evidence for improvements in Norwegian studies implementing 
an MR process as the number of discrepancies and the extensive problem has been 
investigated, but there is no report on the impact of electronical records and the quality of 
information following the transition from paper to electronic journals. Considering the 
limitations of the electronical records, it becomes necessary to measure the effect of 
electronical records on the medicine lists. 
The aim of this master thesis is to determine whether the electronic records provide a 
sufficient accurate patient medication record to negate the need for additional human 
mediated medicines reconciliation. We will do this by comparing the information collected 
from the electronical records, the Prescription Supplier and Summary Care Records, with the 
information collected after the Integrated Medicines Management method, including a 
standardized interview with the patient and the hospital journals/medical curves, which is the 
hospitals list for medication that are prescribed for the patient at the ward. This will give an 
overview and estimation on the impact of electronical records. The discrepancies will also be 
categorized and their potential adverse drug events severity will be determined if they had not 
been identified and therefore give us an idea on the clinical relevance of the discrepancies. 
BOX 1.3 Thesis aims 
The aims of this study is to 
 Determine wether electronic records provide a sufficient accurate patient 
medication record to negate the need for additional human mediated medicines 
reconciliation 
 
 Review the IMM-methodology to determine which elements are required and 
which could be further optimised 
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Furthermore, the IMM-methodology will be reviewed to determine which elements are 



















3.1 Study location, inclusion and exclusion 
The trial was undertaken at the cardiology ward bed unit 1 & 2 at Haukeland University 
Hospital Helse Vest HF in Bergen in the period from October 2015 to January 2016. Patients 
hospitalized at these wards in this period could be included if they fit the criteria. The patient 
criteria were: 
 18 years or older 
 Prescribed at least one medicine prior to admission 
 Consent competent patients who have given written consent for the project pharmacist 
to gain insight into relevant information. 
 Prescribed at least one medicine on admission 
Patients believed it would be difficult to complete a medicines reconciliation was excluded. 
The exclusion criteria were: 
 Unable to provide consent 
 Already received medicines reconciliation when identified 
 Already participating in another trial 
3.1.2 Haukeland University Hospital 
Haukeland University Hospital is responsible for secondary care services in Bergen and 22 
other neighbour counties and delivers care to almost 600 000 patients every year. 
3.2 Sample size justification 
We estimated that within the time period available we would be able to recruit approximately 
40 patients to enable the pharmacy student to perform medicines reconciliation. Once this 
target were reached, we terminated this part of the study. We would like the expert panel 
members to review all discrepancies and therefore 40 patients seems a reasonable and 






3.3 Data Collection 
The project pharmacy student from the University of Bergen completed data collection at the 
hospital. The student visited the ward and completed medication history gathering after the 
IMM-method. 
From the hospitals journal systems including DIPS, following information was gathered: 
 Age  
 Gender  
 Diagnosis  
 Information from former journalnotes or epicrisis’ that can be relevant to the patients 
medicine use  
 Medicine list from last out-patient clinic note and date for data gathering.  
Patients taken out for the study will complete a medicine interview with the gathering of 
following information: 
 Medicines list from the patient or multidose list  
 If the patients administer the medicine themselves or if it is relatives, homecare or 
multidose involved. 
 Information about swallowing or management problems and allergies will be gathered 
from the interview and from the journals. 
 Information on adverse drug reactions 











3.3.1 The medicine reconciliation 
The pharmacy student that undertook the data collection had gone through medication history 
method training at University of East Anglia in fall 2014. A clinical pharmacist from The 
Hospital Pharmacies West also briefly trained the pharmacy student in the IMM-
methodology. The medicine reconciliation interview was undertaken with the first part of the 
IMM-methodology, which is described by the Hospital Pharmacy West HF’s quality system 
(Attachement 1), and with standardised forms that is used by the Hospital Pharmacy West 
and based on the IMM-method (attachment 2). 
Recruited patients received medicines reconciliation, meaning all patients were reviewed by 
the pharmacy student using a Standard Operating Procedure (figure 3.3). The pharmacy  
Figure 3.1 Flow diagram of medicines reconciliation process 
student gathered information on medication from the Prescription Supplier, Summary 
CareRecords, the hospitals electronic and paper journal systems on ward. The findings and 
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From the medicines reconciliation interview following information were strived to be clear: 
 Establish regular medication, for which diagnosis/symptom, and in which dosage 
 Establish medicines taken when needed, for which diagnosis/symptom, and in which 
dosage 
 Establish name, strength dose/frequency of any non-oral preparations 
 Establish use of over the counter medicines, herbal or homeopathic medication 
 Check ability to adhere, both intentional and un-intentional 
 Establish history of adverse drug reactions or side effects to any medication 
 Determine if patient has discontinued medication, and establish reason 
 Establish if there is any medication prescribed for a limited amount of time 
3.4 Classification and management of discrepancies 
The pharmacy student classified the identified discrepancies into 6 different categories 
outlined in table 3.1. 
Classification Description 
1. Incorrect drug name Incorrect drug listed in the records/journals 
than what the patient reports 
Example: 
 Record: Simvastatin – Patient: Atorvastatin 
2. Patient uses different administration 
form 
The drug is listed with different 
administration form in the records/journals 
than what the patient report 
3. Patient uses different dose The drug is listed with different dosage in 
the records/journals than what the patient 
report 
4. Patient does not use drug The drug is listed in the records/journals, but 
the patient reports not using it 
5. Drug Omission The drug is not listed in the records/journals, 
but the patient reports using it 
6. Other If the discrepancy is about something else 
than the classifications mentioned above 
Examples: 
 Not listed day/time for a drug used 
weekly/monthly/irregularly 
 No information on area of use 
 Incorrect allergy information 





3.5 Data processing 
The information on the standardised forms were registered in a Microsoft Excel database.  
In regards to the registration of information, some complications arose that needed to be taken 
into account. Table 3.2 shows the assumptions that are made at registration. 
Complication Assumption/Management 
The date of reconciliation was not properly 
specified on the forms 
Admission date of patient hospitalisation 
was registered 
Some of the discrepancies identified 
concerns “medication” that is not defined as 
drugs, i.e. dietary and nutritional 
supplements 
Everything that was documented from the 
interview was recorded. Those that were not 
relevant were removed from the analysis 
afterwards. 
Information in the hospital journal and 
medical curve were different  
Information from the electronic hospital 
journal was several times outdated, and was 
supplemented with information from the 
medical curve and vice versa when needed. 
The end result would be an overview of 
what the hospital had of medication history 
at admission. 













3.6 Expert panel 
An expert panel consisting of two clinical pharmacists and two doctors were asked to 
independently rate the severity of the discrepancies using a validated scale devised by Dean 
and Barber et al. The Dean and Barber et al. scale(88) developed a validated method of 
scoring the severity of medication errors that did not require knowledge of patient outcomes. 
The severity of errors is scored on each error on a scale from 0 to 10 where 0 is an incident 
with no potential effect on the patient, whereas 10 represents an incident that would result in 
death. Additionally to the scale, the expert panel were asked to state the best and worst case 
scenario regarding each discrepancy using free text (figure 3.2). 
 
Patient 




 Drug Strength Dose Drug Strength Dose Drug Strength Dose   
X 
Metoprol
ol dep. 200mg 1x1 
Metoprolol 
dep. 200mg 1x1 
Metoprolol 
dep. 100mg 1,5x2 Dose 
 
Best case scenario  
Worst case scenario  
Other comments  
 








3.7 Data analysis 
Data analysis or errors will be largely descriptive. Relationship between errors and patient 
type/prescription type and number as explored, but are unlikely to show anything due to the 
small sample sizes. 
The scores from the expert panel was averaged as per published methodology. The free text 
responses will be analysed using content analysis to describe the potential consequences 
which panel membeers believed may have occurred in the absence of the medicines 
reconciliation intervention. 
3.7.1 Exclusion of data in the analysis 
Discrepancies regarding medicines that are not defined as drugs (Nutritional supplements and 
herbal medicine) was excluded from the analysis. 
3.8 Statistics 
The data were analysed in Microsoft Home Office Excel and IBM SPSS Statistics 23. 
3.9 Ethics 
The project were approved by the Regional Ethical Committee for Medical and Health 
Research Ethics and the data gathered were anonymised on the hospital by the project 
pharmacy student. No patient-identity information has been available in the analysis and 
registering of data. 
Written (attachment 3) and oral information were given to patients who met the inclusion 
criteria and their written consent were then if accepted gathered. The patient could withdraw 











Figure 3.3 Standard Operating Procedure (SOP) 
 
 Gather information about patient from medical curve from the patient journal at the ward 
 Patient interviewed to confirm allergy status and medicines being taken  
 GP journalnotes reviewed to confirm allergy status and medicines prescribed  
 Medical notes reviewed to confirm any intentional medication changes due to clinical 
status of patient  
 Other sources of information may have been used depending on availability and relevance 
to current admission by virtue of the date, and included 
 previous electronic discharge letter   
 clinic letter 
 patient’s own drugs (PODs) 
 patients relative or carer 
 nursing home record 
 Multidose system  
 Prescription Supplier and Summary Care Records 


























4.1 Study population 
38 patients were included in the study at Haukeland University Hospital in the period from 
16th of November 2015 to 22nd of January 2016. Two of the included patients was excluded as 
it was not possible to complete a medicines interview and reconciliation with both of the 
patients after receiving consent. 36 patients were therefore included in the further analysis. 
Table 4-1 shows an overview of the patient demographics. A total of 23 (63,9%) that were 
included were men, and 13 (36,1%) were female. The mean (SD) age for the patients were 
69.8 (9.7), all patients administered their medication themselves and used a mean (SD) of 
6.97(3.03) drugs.  
 
Table 4-1   Patient demographics 
 Measure Study population (n=36) 
Age Mean (SD) 69.8 (9.7) 
Female N (%) 13 (36.1) 
Self management of 
medications 
N (%) 36 (100%) 













Most of the included patients used a total amount of 9 medicines (27,8%), while 13,9 % used 5 or 6 
drugs. Maximum amount of drugs were 12 drugs (5,6%) , while the fewest amount of drugs were 1 in 
total (5,6%). 
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4.2 Discrepanies identified 
Figure 4 presents a flowchart overview over the inclusion and exclusion of data. The project 
pharmacist identified a total of 138 discrepancies in the 36 included patients and their 
medicine lists in the hospital journal and electronical journal. Discrepancies involving non-
drug pharmaceuticals, for example vitamins, unknown herbal remedy or medical equipment, 



















Figure 4-2 Chart of inclusion and exclusion of data and discrepancies for analysis 
 
Table 4-2 presents the numbers of discrepancies identified at MR in the hospital journals and 
electronical records. The electronical record medicine lists had the exact same amount of lists 
with discrepancies identified with MR (72,2%) as the medical curve/hospital journals, and 
there were in total 30 patients that had a list with discrepancy (83,3%). Although, the 
electronical records had a higher total amount of discrepancies (53 vs. 57) and therefore also a 
higher mean number of discrepancies per list with at least 1 discrepancy than the medical 
38 initially included 
patients 
36 patients analysed 
138 discrepancies 
2 excluded patients 
- Not possible to 
conduct a patient 
interview 
Exclusion of non-drug 
pharmaceuticals, herbal 
remedies and medical 
equipment 
67 discrepancies in 
hospital journals 




curve/hospital journal (2,58 vs. 2,73). At most we found 8 discrepancies in the electronical 
records and 6 in the hospital journals. For one patient, we found 11 discrepancies in the 











26 (72,2) 26 (72,2) 30 (83,3) 
Lowest/Highest amount 
of discrepancies 
0/6 0/8 0/11 
Mean number of 
discrepancies per 
patient 
1,86 1,97 3,83 
Mean number of 
discrepancies per list 
with at least one 
discrepancy 
2,58 2,73 4,53 
Table 4-2 Discrepancies identified at MR in the hospital journals and electronical records.  
 
4.3 Categories of discrepancies/errors identified in total 
Table 4-3 presents an overview of the categories of errors and the distribution among them. 
The three most common errors were categories into “Patient uses different dosage” (20,97%), 
“Patient does not use drug” (35,48%) and “Drug Omission” (37,90%).  
Error type Amount of errors Amount of errors % 
Incorrect drug 5 3,62 % 
Incorrect dose 30 21,74 % 
Patient does not use 
drug 
52 37,68 % 
Drug Omission 49 35,51 % 
Other 2 1,45 % 
Total 138 100,00 % 




Figure 4-3 displays the distribution of the medicines’ ATC-groups identified at MR. 
Cardiovascular medicines (29,5%) were the most common drug involved in the discrepancies, 
followed by drugs for the nervous system (15,6%), respiratory system(14,8%) and alimentary 
tract and metabolism drugs (13,1%). 
 
Figure 4-3 Distribution of ATC-code of the drugs identified as discrepancies at MR.  
In Table 4-4, the medicines involved in the discrepancy category “Incorrect medicine” is 
displayed. 8 drugs were involved, whereas Pantoprazol and Esomeprazol were both involved 
twice. 
Incorrect medicine Correct medicine 
Pantoprazol Esomeprazol 




Table 4-4 Overview of medicines involved in the category “Incorrect medicine” 
 
Table 4-5 presents the medicines that were involved in the discrepancies with incorrect dose. 
Ramipril and Levothyroxin were the most common drugs in this category with four 
discrepancies each, followed by Metoprolol depot and Bumetanid. There was most frequently 
drugs from the ATC-group C, Cardiovascular with 14 of 30 (46,7%) discrepancies. 
0,0 % 5,0 % 10,0 % 15,0 % 20,0 % 25,0 % 30,0 % 35,0 %
Alimentary tract and metabolism (A)
Blood and blood forming organs (B)
Cardiovascular system (C)
Dermatologicals (D)
Genito-urinary system and sex hormones (G)
Systemic hormonal preparations (H)
Musculo-skeletal systems (M)
Nervous system (N)











Alimentary Tract and Metabolism   
Metformin A10 1 0 1 
Calcigran Forte A12 1 0 1 
Blood and bloodforming organs   
Rivaroksaban B01 1 0 1 
Acetylsalicylic acid B01 1 1 0 
Cardiovascular system    
Ramipril C09 4 3 1 
Metoprolol dep. C07 3 2 1 
Bumetanid C03 3 3 0 
Bisoprolol C07 1 1 0 
Hydrochlorthiazid C03 1 0 1 
Karvedilol C09 1 1 0 
Atorvastatin C10 1 0 1 
Systemic Hormonal preparations     
Levothyroxin H03 4   
Prednisolon H02 1 1 0 
Nervous System    
Levodopa/Karbidopa N04 1 0 1 
Pramipexol N04 1 0 1 
Olanzapin N05 1 0 1 
Respiratory System (R)    
Budesonid/formoterol inhalation R03 2 1 1 
Tiotropiumbromid inhalation R03 2 2 0 
Terbutalin inhalation R03 1 0 1 
Sensory Organs (S)    
Timolol/dorzolamid S01 1 1 0 
Table 4-5 Overview of the drugs involved in the category “Incorrect dose”.  
 
Table 4-6 presents the medicines and ATC-groups involved in the discrepancies in the 
category “Patient does not use drug. Furosemid (4), Amiodarone (3) and Pantoprazol (3) were 
the most frequent drug involved in this category. 
Table 4-7 shows the medicines and their ATC-groups for drugs missing from either the 
electronical record, hospital journal/curve or both. The most frequent medicine missing were 
Salbutamole inhalation and Diclofenac. Drugs in the ATC-group Nervous System were most 





Drug ATC Total errors 
Alimentary Tract and Metabolism 
Pantoprazol A02 3 
Natriumfluorid suspension A01 1 
Metformin/Vildagliptin A10 1 
Loperamid A07 1 
Blood and bloodforming organs 
Acetylsalicylic acid B01 2 
Tranexamic acid B01 1 
Rivaroksaban B01 1 
Cardiovascular system  
Furosemid C03 4 
Amiodarone C01 3 
Ramipril C09 2 
Simvastatin C10 2 
Ezetimib C10 2 
Rosuvastatin C10 2 
Bumetanid C03 1 
Atorvastatin C10 1 
Nitroglycerin C01 1 
Lerkanidipin C08 1 
Dermatologicals  
Betametason/kalsipotriol topical D07 2 
Mometasonfuroat topical D07 2 
Betnovat w/ chinoform topical D07 1 
Betnovat liniment D07 1 
Mikonazol/Hydrocortison D01 1 
Genito-urinary system and sex hormones 
Dutasterid/tamsulosin G04 1 
Musculo-skeletal systems 
Denosumab injection M05 1 
Nervous system  
Mirtazapin N06 2 
Escitalopram N06 1 
Levomepromazin N05 1 
Oxazepam N05 1 
Levetiracetam N03 1 
Paracetamol N02 1 
Respiratory System  
Fexofenadin R06 1 
Desloratadin R06 1 
Etylmorphin R05 1 
Indakaterol inhalation R03 1 
Tiotropiumbromid/Olodaterol inhalation R03 1 
Terbutalin inhalation R03 1 




Drug ATC-group Total errors 
Alimentary tract and metabolism 
Sennaglycoside A06 2 
Insulin Aspart A10 1 
Triobe A11 1 
Calcigran Forte A12 1 
Esomeprazol A02 1 
Pantoprazol A02 1 
Blood  and blood forming organs (B) 
Acetylsalicylic acid B01 3 
Vitamin B12 Depot injection B03 1 
Cardiovascular system   
Glyceroltrinitrate C01 1 
Amiodarone C01 1 
Pravastatin C10 1 
Ezetimib C10 1 
Atorvastatin C10 1 
Metoprolol depot C07 1 
Valsartan Hydrochlorthiazid C09 1 
Dermatologicals  
Mikonazol/Hydrocortison D01 1 
Genito-urinary system and sex hormones 
Vardenafil G04 1 
Tadalafil G04 1 
Estradiol Vaginals G03 1 
Systemic Hormonal preparations 
Prednisolon H02 1 
Musculo-skeletal systems 
Diclofenac M01 4 
Nervous system  
Zopiclone N05 3 
Paracetamoll/Codeine N02 3 
Klozapine N05 1 
Oxazepam N05 1 
Olanzapine N05 1 
Paracetamol N02 1 
Respiratory System  
Salbutamole inhalation R03 4 
Etylmorphin R05 1 
Fluticasone/Salmeterol inhalation R03 1 
Budesonid/formoterol inhalation R03 1 
Terbutalin inhalation R03 1 
Fluticasone furoate/vilanterol inhalation R03 1 
Sensory Organs (S)  
Timolol/dorzolamide S01 1 
Tafluprost S01 1 





In table 4-8 we find the distribution of second level of ATC-groups in the different 
categories. Betablocking agents were most common in incorrect dose, Dermatological 
Corticosteroids for “Patient does not use” and drugs for Psycholeptics in “Drug Omission”. 
Table 4-8 Distribution of the most commonly ATC-groups involved in the different error 
categories identified at MR. 
 
 
 ATC-Code Count % 
Incorrect drug    
Drugs for acid related disorders A02 2 40,0 
Diuretics C03 1 20,0 
Agents acting on the renin-angiotensin system C09 1 20,0 
Lipid modifying agents C10 1 20,0 
Incorrect dose    
Beta blocking agents C07 5 19,2 
Drugs for obstructive airway diseases R03 4 15,4 
Diuretics C03 3 11,5 
Agents acting on the renin-angiotensin system C09 3 11,5 
Antithrombotic agents B01 2 7,7 
Thyroid therapy H03 2 7,7 
Anti-Parkinson drugs N04 2 7,7 
Drugs used in diabetes A10 1 3,8 
Mineral supplements A12 1 3,8 
Lipid modifying agents C10 1 3,8 
Corticosteroids for systemic use H02 1 3,8 
Patient does not use    
Corticosteroids, dermatological preparations D07 5 11,4 
Cardiac therapy C01 4 9,1 
Diuretics C03 4 9,1 
Lipid modifying agents C10 4 9,1 
Drugs for acid related disorders A02 3 6,8 
Drugs for obstructive airway diseases R03 3 6,8 
Antithrombotic agents B01 2 4,5 
Antifungals for dermatological use D01 2 4,5 
Psycholeptics N05 2 4,5 
Psychoanaleptics N06 2 4,5 
Drug Omission    
Psycholeptics N05 7 14,9 
Drugs for obstructive airway diseases R03 7 14,9 
Analgesics N02 4 8,5 
Antithrombotic agents B01 3 6,4 
Lipid modifying agents C10 3 6,4 
Anti-inflammatory and antirheumatic products M01 3 6,4 
Drugs for acid related disorders A02 2 4,3 
Cardiac therapy C01 2 4,3 
Urologicals G04 2 4,3 
Thyroid therapy H03 2 4,3 
Ophthalmologicals S01 2 4,3 
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4.4 Clinical relevance score 
The expert panel scored all the discrepancies found in our study, and table 4-9 displays the 
lowest/highest mean score of one discrepancy, the lowest/highest individual score* of one 
discrepancy and the total mean score of all the discrepancies in the specific categories. The 
“other” category, consisting of two allergy information discrepancies between the records 




Lowest score of 
discrepancy 







Incorrect drug 0,25 3,75 0/7 2,00 
Incorrect dose 1,25 5,00 0/10 2,96 
Patient does not 
use drug 
0,50 6,00 0/10 2,43 
Drug Omission 0,75 6,00 1/10 2,53 
Other 8,25 8,25 7/10 8,25 
Table 4-9 Clinical relevance score of each discrepancy category 































5.1 Main data 
Electronic records were introduced to reduce errors and improve communication between 
healthcare professionals and settings, and hence reduce the opportunity for error. The results 
from this small scale study suggests that this assumption is incorrect. With at least one error 
identified in around one third of the patients the potential for harm due to miscommunication 
remains. In addition to that, we found that there were around four discrepancies per patient 
when looking at their hospital and electronic records. 
The most common error was found to be that there were drugs that the patient did not use 
even though the records stated so. Which means that the potential implication is patients 
receiving drugs that they do not have any need for and presents the potential harm. The other 
frequent discrepancy that we observed were incorrect doses and drugs omitted 
When considering the types of medication, we find that the most common drugs were found 
to be Ramipril and Albyl-E. The severity of errors was on average found to be 3,6 using the 
Dean scale, however there were discrepancies that were rated over 8 by an individual in the 
expert panel 23 times, which means that there were multiple errors in our study that the health 
professionals considered to be potentially deadly. 
 
5.2 Method discussion 
5.2.1 Strengths of the study 
We asked an expert panel of 2 pharmacists and 2 senior doctors to assess the discrepancies 
found between the 3 sources of information that were available. The expert panel used a 
validated scale devised by Dean and Barber that were found appropriate to assess errors 
without requiring knowledge of patient outcomes(88). In the scoring sheet we saw variances 
that were largely seen between the two professions that were asked to score the clinical 
significance. Previous studies have concluded that judges of different professions differ in 
their assessment of errors, which is also seen here(89, 90). On the contrary, we can also find 
studies that also show differences among individuals where multiple health personnel from 
the same profession has participated(88). We found it appropriate to ask 4 judges from two 
52 
 
different professions that has clinical experience to score the medication errors. Patient were 
also consecutively included and there were few exclusion criteria’s.  
 
5.2.2 The limitations of the study 
The study setting and location is set at one hospital at one ward in Western Norway. The 
results of the study will therefore be of limited generalisability to other hospitals and wards 
and ideally, the study would be performed at several wards in several hospitals in the country 
to increase generalisability. The patients selected for recruiting into the study where 
performed by both the project pharmacist and head nurses at the ward. The nurses were not 
always available and free when the project pharmacist was at ward, so the selection would 
have to be done by the project pharmacist with the consent of the nurse, which would 
potentially introduce bias favouring selection that would benefit the intervention.  
The recruiting of patients were also performed occasionally in times of less busy parts of the 
day because the nurses have a hectic schedule. This would present patients that would be 
more friendly and positive to intervention and also patients that would have a social 
desirability and therefore prone to self-selection. Patients not interested in participating may 
do so because of fatigue and the consequence is a less variated study population and inclusion 
of patients that may not be the ones in need of the service. Ideally, there would be an 
independent recruiter for the study and the patients that were not able to participate would 
create more difficulties for anyone performing MR and therefore would produce different 
results. The study population is small in this study and we would have more power in our 
identified findings if we had a larger sample size.  
The results in this study has not differentiated between intentional and unintentional 
discrepancies found between the different sources. In those cases that an intentional change in 
the patients medication at admission has been done, but not documented properly in the 
medical curve or patient journal, the change has been registered as an discrepancy. 
Consequently the number of discrepancies is potentially overestimated. The project 
pharmacist would also have more time to perform MR than an individual providing care and 





5.2.3 Project Pharmacist 
In this study, the student, who is not a trained clinical pharmacist is conducting the interviews 
and is also the one doing the medicine reconciliation, and therefore it would not be 
improbable that a more trained and experienced pharmacist would identify additional errors 
and discrepancies, and gotten better results. The student pharmacist were introduced to the 
IMM-method and its procedures by his supervisor and underwent briefly training in the 
procedure before conducting the interviews with the patient because of shortage of time. In 
addition to that, the project pharmacist underwent further training by the supervisor a little bit 
later into the inclusion period from December, meaning that the project pharmacist improved 
his reconciliation and interview skills and, therefore given some of the patients included in the 
study enhanced reconciliation to some patients than other. If the student underwent more 
training at the beginning and also had the opportunity to practice and refine method skills to a 
larger extent before interviewing all the patients, the intervention might have been improved 
throughout the study. A study conducted an educational campaign targeting junior doctors and 
included teaching, posters and placing reminders in the hospital notes. They included 580 
patients and the discrepancy rate per patient on discharge summaries significantly reduced 
from 2.6 in the pre-educational intervention, to 1.0 by the end of the study. The decline also 
remained significant when only clinically important discrepancies were included(91). This 
supports that teaching activities could improve medicines reconciliation performance to an 
extent. 
 
5.3 Integrated Medicines Management and Standardised Reconciliation Document 
The study shows that the IMM method used for a medicines reconciliation process might be 
appropriate to record discrepancies in the medicine list between the different sources in a 
cardiologic ward setting. The study population in our study was relatively old compared to 
other studies in Norway and were also diagnosed before admission according to the hospital 
journals and therefore already used a number of drugs, which is expected from a cardiologic 
ward. The inclusion criterias in the IMM-method from Northern Ireland were one of the 
following; use at least 4 regular drugs at admission, use one high risk drug, takes 
antidepressants, is 65 years old and/or has been hospitalised the last 6 months(27). The 
LIMM-model from Sweden included patients over 65 years and atleast one regular drug on 
prescription(64). The inclusion criterias resemble the patients included in our study as the 
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mean age was 69.8 years and all patient had at least one regular drug.  Past studies in other 
wards in Norway display that there is an appropriate method to use in other wards and in 
patient groups with lower age, but nonetheless also shows that high age and higher amount of 
drugs at admissions are risk factors for discrepancies. The IMM-method can therefore be 
appropriate for other wards in other hospitals in Norway. 
The integrated medicines management method and use of standardised MR forms to ensure 
optimum implementation could contribute to better communication of information. There is 
limited evidence on the impact of electronical records, but those reported has shown a 
significant reduction in both discharge summary omissions and medication errors with the 
potential to decrease health resource utilisation(92, 93). 
The standardised forms used for conducting the medicine reconciliation from the IMM-
method in Norway contains the gathering of essential key points that is relevant for a 
reconciliation. That includes patient identity, information on medication, checking their 
ability to adhere, adverse drug reactions and drug allergy. The form is designed so that the 
information from the medical curves goes in as the main information, and then discrepancies 
from other sources is recorded under “dosage*”. At times the information on the medical 
curve will not contain information on what drugs the patient used before admission, and 
therefore it should be stated where the main information is collected from, whether it is the 
curve/cardex or other sources. It is also not clear where information on drugs that are not 
documented in the medical curve should be recorded on the form. The procedure assume that 
the hospital medical curve or journal contains all the drugs that the patient use, which is more 
often not the truth. 
The procedure of the IMM-method also contains a checklist on drug groups that is expected 
of the pharmacist to check through in the interview. The checklist provides an overview of all 
the groups that might be relevant to ask for further information, but it is often not appropriate 
to ask all of them. The procedure might be impracticable time wise and removes porfessonial 
decision making and discretion. In other words, a good professional will tailor their MR 
process accordingly, to some extent individually and identify all of the main issues efficiently 
without needing a tick box. Furthermore, the checklist designates and causes the interview to 
consist of closed questions and this might lead the interview to be experienced more as an 
interrogation from the patients perspective. An interview with more open questions is 
preferable as the interviewer might pick up information that is relevant in a two-way dialogue 
where the patient can speak more freely instead of answering yes or no questions.  
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The standardised forms that the Hospital Pharmacies use from the IMM-method is also 
developed before the introduction of the electronical Summary Care Record that makes it 
easier to collect and record all the prescriptions that the patient has. Furthermore, Haukeland 
University Hospital implemented electronic medical curves that the cardiologic ward now 
use. The electronical curves directly downloaded the information from the Prescription 
Supplier/Summary Care Record so that information on all prescriptions now is directly set 
into the hospital curve. From the results it is evidence that there is an amount of discrepancies 
between the Summary Care Record and what the patient real drug use is. The standardised 
forms should take into consideration the synchronization between the medical curve and 
electronical records and an intervention aiming to reduce the discrepancies between the two 
different sources. 
Developing and incorporating a standardised form is not free of challenges. Underutilisation 
and unfamiliarity of the staff with form might be problematic and be perceived as confusing 
and time consuming and thus contribute to reduced quality in care transition(93). However, 
experience with the form would build up and thus form completion might improve and 















5.4 Result discussion 
5.4.1 Impact of electronical records 
The numbers for the percentage of lists with discrepancies (83%) was found similar to other 
studies. Our results agrees with a previous Norwegian study that looked at discrepancies in 
medicine lists with atleast one discrepancy from Tromsø (84%) and summarized data from 5 
studies in Oslo (79%)(37, 94-98). Another study from Oslo found a rate of 70%, while three 
others found a lower rate of 53% and 47% at different hospital settings(99-101). In 
international studies, it has been observed that medicine lists discrepancy rate varies from 
16,8% to 85%(31, 32, 92, 102-113). This is confirmed by multiple reviews including Tam et 
al. (67%) and Lehnbom et al. that showed a variation between 3,4 – 98,2% in a review from 
2014. The big differences and variation can be explained from different study designs and 
different study population, 
The mean number of discrepancies per list were found comparable and agreeable to the past 
studies. Norwegian numbers has shown mean numbers of 3,2 discrepancies per list(37, 94-96, 
98, 100, 101), while international studies has shown an average up to 2,3 discrepancies(73, 
102, 105, 107, 108, 110). The data is though not directly comparable since the international 
studies is conducted in countries with very different health systems and structures. The studies 
also differ in patient demographics, in their presentation of outcome measure, as some present 
per list with at least one discrepancies and others as just per list, they vary in what type of data 
that is included or excluded and differ in study setting. It would be more appropriate to 
compare our numbers with the Norwegian studies that has used the same methods as ours. 
Our study shows that our numbers concur with or is slightly higher than studies that uses the 
same IMM-method, but those studies are without the use of electronic records. Our proportion 
of discrepancies is higher than multiple studies, and this might be explained by the high age 
average, high mean amount of drugs and the higher amount of men in the study(94-98). 
There is though no big difference between our study and the one summarized study from Oslo 
in regard to amount of lists with discrepancies (79% vs. 83%). The patient demographics did 
not differ very much in age (73 vs 69,8) or amount of drugs (6,0 vs. 7,0), but mean average of 
discrepancies showed a very higher amount in our study (3.0 vs. 4.53). There is no evidence 
on a great impact of electronical records compared to the other studies in Norway (table 1.1) 
as our study seems to either contain around the same amount of lists with discrepancies and 
the same or higher rate of discrepancies per list.  
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The electronical records containing invalid or old prescription lines of medications that the 
patient does not use more, from the GP or other doctors might explain this. GPs, hospital 
doctors and other secondary care doctors all have the possibility to prescribe medicines into 
the electronical record database, but is it not clear who have the responsibility to clean up and 
delete invalid or old prescriptions. The GP law regulations states that the main responsibility 
lies within the GP to coordinate the patients drug therapy(114), but a Danish study from 2015 
concludes that GPs does not know enough about when and how to discontinue medication, 
and moreover that they lack the support to do so(115). This includes that the GPs does not 
always have a clear picture of when the treatment is no longer needed. The study also states 
that the doctors lack the government support to discontinue medicine, thus a solution to this is 
to develop guidelines for doctors to stop medication. For example, the Norwegian government 
has adapted the START (Screening Tool to Alert doctors to Right Treatment) and STOPP 
(Screening Tool of Older People’s potentially inappropriate Prescriptions) tools, Europe’s 
most used assessment tool to Norwegian conditions(116). The tools’ purpose is to reduce 
unfortunate drug use in elderly patients, and feedback states that the tools is useful as an aid to 
decision-making in clinical practice. Implementation of these and similar tools or guidelines 
for younger patients may contribute to medicine lists that is more accurate.  
The consequence of not discontinuing is that the GPs continue to prescribe medications, their 
own and other secondary care doctors medications even though there is no more benefit for 
the patients in continuing their medication. This might be a problem with the introduction of 
the Norwegian electronical records, and the GPs might have a little too much respect to take 
action against what specialists prescribe considering . However, discharge summaries is often 
written by junior doctors with limited experience and a senior doctors signature is no 
guarantee of quality due to time pressure. Discontinuing medication might be a way to 
prevent patient harm caused by side effects and the research therefore shows that the doctors 
are motivated to stop the medications, but abstains from doing so because they are perplexed 
about how they should address it.  
Another problem might be that the GPs, hospitals and pharmacies use different computer 
systems to prescribe, recall and dispense medication. Therefore it may be difficult to 
communicate when the different care settings does not have each others perspective on how 
the medicine lists actually look like. The pharmacies use a common system, the GPs does not. 
Feedback from some of the GPs is that their system does not automatically show for instance, 
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when there is a double prescription on the same drug. A common system among the GPs that 
communicates well with the systems in the hospital and pharmacies should be aimed for. 
The consequences of no one organizing or cleaning up the patients’ prescription lines is a 
potential inaccurate overview of what the patient really uses. Hospital doctors then might 
have to use time and resources to research and find out what the patient actually use at 
admission to the hospital or even worse, that they base their decisions on further therapy on 
information that is wrong. Another consequence that could happen is when the pharmacy 
dispense medication to the patient, that they have several alternatives on the same drug 
because no one deleted the old prescription. The different drugs might also have different 
dosage and the pharmacy can assume that the newest prescription is the right one, but they do 
not know. Pharmacy staff might also have the belief that they should dispense and use up the 
old prescriptions first, as many GPs automatically renew their patients. This leads to the 
assertion that multiple prescription lines on the same drug increases the risk for medication 
errors. 
The hospitals in Norway will gradually transfer to electronic medical curves and lists, which 
had already started happening at the ward where this study was conducted. The e-curves will 
gather all information on medication use and transfer it automatically to their system, 
including the data from the electronical Summary Care Record and Prescription Supplier. 
Therefore, old, unused and invalid prescriptions will also be automatically transferred to the 
e-curves and the hospital system. The errors will follow from record to record, which the staff 
have to correct. It is also a tendency that the easier it is to transfer data to the electronical 
curves at admission the easier it is to accept that the list that is transferred in from the 
electronical records is correct as they are, and therefore accepted without reconciliation. The 
consequence is far more errors in the medicine lists than what has previously been the case 
before. 
The implementation of electronical records show that medicine information transfer more 
effectively and safer between different settings of care, but this has also introduced new 
challenges and barriers that must be solved. The patients will still be the ones that has the 
complete and true information on what they actually use of their prescriptions. Moreover, they 
also hold information on herbal medicines, over the counter medicines, supplements and other 
drugs that the electronical record does not collect. Our results showing that 83% of the 
patients had a discrepancy in their hospital journals/curves or electronical record is a number 
that should aimed to be reduced. The medicine list is a part of the foundation for diagnosis 
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and further treatment at the hospital, thus it is important that they contain correct information. 
If an error has occurred, there is a possibility that the error continues to persist in other 
systems. In that way further treatment may be decided on the wrong basis and in worst case 
may be the source of an adverse drug event. As our results show no great reduction or 
improvement in the amount of discrepancies compared to the studies without the use of 
electronic records, it seems that there would be a need for human intervention to secure 
accurate medicine lists at the hospital.  
 
5.4.2 Types of discrepancies, drugs involved and their clinical relevance 
The most frequent discrepancy that we observed in the category “Patient does not use drug” 
(38%) is slightly higher than some other studies in Norway(36, 95-98, 101, 117). 
Additionally, we found that “Drug Omission” (36%), and “Incorrect dose” (20%) were 
observations that agrees with previous national and international studies(37, 72, 95-98, 101, 
103, 107, 109, 112, 117). The fact that we observed a higher rate of drugs that the patient did 
not use may be due to the effect of the electronical record that gather all information on all the 
patients’ prescriptions and interprets them all as drugs in use. That adds up to errors that has 
previously been discussed because no personnel takes responsibility in clearing up 
prescriptions in the records. For drug omission, we can observe that drugs involved in this 
category can be categorised as PRN drugs, medication that is taken when needed. We also 
observe that some of the drugs that are involved can be categorised as “Over The Counter” 
(OTC) drugs which you can buy at the pharmacy without prescription, for example 
Diclofenac and Sennaglycoside which is two more frequently involved drugs. Since the 
electronic records only display drugs on prescription in their database, this category of drugs 
will not be picked up at admission unless there is human intervention. There is also no way 
for the hospital journals to automatically pick these types of drugs up in their systems. The 
drugs in this category might arguably be of little importance to the patient since most of them 
are considered PRN drugs and the patients would tell the staff at the ward if they would have 
a need for them. However, one possible implication is in circumstances, for example acute 
situations where there is no opportunity to communicate directly with the patient and that 
leads to the hospital possibly not  having an accurate and complete medicine list when making 
their decisions. One solution to reduce the amount of drugs omitted and reduce the amount of 
errors of drugs that the patient does not use is to communicate directly with the patient where 
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there is possible, for example in a MR process. Only the patients have the complete truth 
about their medications, adherence and recent changes that might not be in the journals. 
Our distribution of the drugs among the ATC-groups agrees with previous studies, where they 
have found that the most frequent drugs involved in the discrepancies has belonged in the 
ATC-groups A, C and N(34, 37, 72, 92, 94, 96-98, 101, 105, 106, 109-112). ATC-group A 
(Alimentary Tract and metabolism) is the fourth most common ATC-group in our study, so 
this also agrees well with the other studies. That ATC-group C is our most frequent 
discrepancy group is expected since our study takes place in a cardiologic ward, and our study 
additionally has similarities to previous ones, including a high mean age. The fact that drugs 
in group N, R and A is among the other most frequent is likewise not very surprising since 
those three groups is among the most dispensed drug groups nationally.  From the Institute of 
Public Health drug statistics, drug group N (13,31%), R (12,51%) and A (9,09%) were three 
of the five highest used drug groups in Norway in 2015(118). The other two groups are C 
(10,38%) and J (Antiinfectives for systemic use)(11,95%). 
In the second level of distribution among ATC-groups, Psycholeptics (N05), drugs for 
obstructive airway diseases (R03) and analgesics (N02) are the most frequent discrepancies in 
“drug omission”. This agrees with the results from Holmestad et al. in 2015 and Hellström et 
al. from 2012(64, 117). These types of drugs are typical PRN drugs. This agrees with our 
earlier notion since Salbutamol, Paralgin Forte and Diclofenac is the drugs most frequent in 
this category. Our and previous results therefore indicates that these are typical drugs that 
does not get picked up at admission. Since they are drugs that might not be part of the patients 
daily routine, the patients might forget to mention them, and the doctors might forget asking 
about them and therefore not register them in the discharge summaries.  
For the category “patient does not use”, the most frequent groups were in Dermatological 
corticosteroids (D07), Cardiac Therapy (C01), Diuretics (C03) and Lipid modifying agents 
(C10). This does not completely with the other studies, which had frequently drugs in the 
ATC-group A(117), but may again be a result of the study setting. Dermatological 
Corticosteroids is a typical as needed drug and might be used temporary or as a cure, and that 
the prescriptions or drug information has not been updated, deleted or completed might be the 
cause for the frequent discrepancy. This also includes diuretics that might be used temporary 
for water retention, such as Furosemide which is the most frequent drug involved in this 
discrepancy category. For Cardiac Therapy drugs that were involved, we observed that 
Cordarone were three out of four discrepancies. The doctor may have discontinued the 
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Cardiac Therapy drugs and Lipid modifying drugs and so the prescription might linger from 
previous time. It may have occurred so because of adverse drug events, as Cordarone and 
lipid modifying agents such as statins are commonly associated with side effects, though we 
do not have enough data to conclude on this.  
The same reasons might also be applied for discrepancies in the “incorrect dose” category, 
where beta blocking agents, such as Metoprolol depot and Bisoprolol, and drugs for 
obstructive airway diseases are the most common. In the case for beta blocking agents being 
involved, the general rule is “start low, go slow” with these types of drugs and other blood 
pressure medicines, where you usually start with a low dose, and gradually increase until you 
reach lowest effective dose. The dose will therefore frequently change until you reach the 
right dose and might explain why we find several discrepancies with incorrect dose for this 
ATC-group and Ramipril which is frequently involved. The same explanation can be applied 
to why Levothyroxin (Levaxin) is the most common drug involved in this category, since the 
dose is individual set and controlled by TSH-values. The initial dose is likewise low and then 
gradually increasing every 4th- 6th week until you reach a maintenance dose(119). In the case 
for drugs in ATC-group R03, drugs for obstructive airways, several types are typical PRN 
drugs and may therefore also vary in dosing. It is consequently not surprising that we find 
them in the category “incorrect dose”. The possible implications is that the patient receives a 
wrong dose and that they are under or over treated because the records is not updated or just 
contains an input error. The same solution for the frequently errors in drugs that the patient 
does not use may be applied here, that there is a need for a health personnel that has the 
responsibility to coordinate the prescriptions in the record, such as the GP which regularly 
communicates with the patient. 
On the active substance level numerous drugs is repeatedly recurrent in past studies looking at 
the most frequent ones, though most studies vary in what their most common drugs. In the 
Norwegian studies from 2012 paracetamol, glyserolnitrate, zopiclone, diazepam and 
paracetamol/codeine is observed most frequent(94, 96-98, 101). Holmestad et al. found 
paracetamol, zopiclone, oksazepam, salbutamol and paracetamol/codeine as theirs(117), 
whilst a study in Northern Norway found ibuprofen, paracetamol, zopiclone, oksazepam and 
salbutamol as their most frequent(37). In our study, we find Ramipril and Albyl-E as our most 
frequent drugs which again may be a result of conducting the study at a cardiological ward. 
When we look at drugs not among the ATC-group C, we observe that Somac, Salbutamol and 
Zopiclone are among the most frequent, agreeable to an extent with previous studies and 
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which again also strengthens the theory that typical PRN drugs does not get picked up at 
admission.  
In the clinical relevance score for each of the discrepancy type, we see that the 2 discrepancies 
in the category “Other” have the highest mean score with 8,25 out of 10 from the expert 
panel. The two discrepancies in this category were related to incorrect information on the 
patients drug allergies. One of the individuals in the expert panel commented that the 
discrepancy in the electronical record on the error in the allergy information might be deadly 
if the patient is admitted to another hospital and does not find the correct information in the 
electronical record. In the category “incorrect drug” the mean score were 2,00 and suggests 
that the discrepancies in this category is of little potential effect to the patient. Even though 
the medicine lists contains the wrong drug name or a drug of the same kind, the patient is still 
getting treatment for their diagnosis and this reflects the low score for clinical significance for 
this type of discrepancy. 
We find that “Incorrect dose” has the highest mean score of all the categories with a score of 
2,96, while “Patient does not use drug” and “Drug Omission” was respectively scored 2,43 
and 2,53. The scores indicates that the errors is generally of little to moderate significance, 
with a low potential for effect on the patient. This supports the note that a relative amount of 
discrepancies is caused by PRN medicines and therefore, the panel would not find it of high 
significance if the patient does not take it or the hospital does not record it. However, there are 
discrepancies of high significance, displayed by that some of the discrepancies were scored 10 
by individuals in the panel, meaning there were errors among the discrepancies that were 
scored potentially deadly for the patient. In our study, 23 discrepancies where rated 8 or 
higher by an individual in the expert panel, meaning that there were multiple discrepancies in 
the study that some in the expert panel found to be of potential severe harm to the patient. For 
example we found a discrepancy where the electronic journal systems stated that the patient 
used Amiodarone, which was not the case. With the new electronic curve system that 
automatically download the information from the electronic records, there would be an 
potential of error where the patient was given Amiodarone unnecessary and be potentially of 
harm. However, the highest score for an individual discrepancy by the four health 
professionals in the panel were 6.00, if you excluded the two allergy discrepancies. Even 
though there were 23 discrepancies with an individual rating of 8 or higher, but no higher total 




5.5 Improvement suggestions and research needs 
Our studies results put forward that even with the introduction of electronical records that 
there is a need for human intervention along with new digital solutions that aim to improve 
communication between care settings. Comparisons between our study and similar studies 
without the use of electronical records show no great difference and seem to be showing the 
same results. Our study is the first one to research the impact of the e-records after their 
introduction in Norway, and to conclude certainly on this there will be a need for bigger and 
generalizable studies. Our observations might also be a result of health personnel not being 
entirely acquainted to a new system and time might be needed for the fully effects of the e-
records to take place in an everyday with already a lack of time. Health personnel might also 
need time to get used to and implement the new digital tools into their daily routine. In this 
study, we experienced that the staff on the ward minimally used the Summary Care Record 
(SCR), and with time and experience the effects might progress.  
Though, the introduction of e-curves presents a new challenge where the information from the 
electronical records are automatically downloaded to the hospitals, and therefore all 
prescriptions is set into the hospital records and medical curves. Our study shows that the 
electronical records often contain discrepancies because no one organizes the old 
prescriptions the patient is using, and therefore the information in the e-records are often 
false. A solution to clean up and organize the prescsription list in the e-records must be 
established. The natural solution is to guide the GPs to do this task since they have the 
patients’ full medical history and know the patients best themselves. The studies show that 
one of the barriers that obstructs GPs to discontinue medication is the lack of government 
support to do so. Thus, guidelines to support GPs to organize their patients’ prescription lines 
might be a solution to more accurate electronical records.  
Implementing medicine reconciliation and including pharmacist service might be a good 
initiative to securing accurate medicine lists, and the Patient Safety Program started by the 
government is setting a nationwide focus on this. Studies show that the IMM-model can 
contribute to increase the quality of drug therapy(100). Additionally, several countries has 
implemented medicine reconciliation as a patient service, though they are countries with 
different health systems and we do not know if their studies also apply to the Norwegian care 
settings. The studies in Norway are moreover of less robust design and are not of appropriate 
outcome measures to fully conclude on the benefit of medicine reconciliation for the patients. 
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Moreover, the IMM-method should be adapted to Norwegian conditions, as the Swedish has 
done with the LIMM-method.  
Multiple hospitals in Norway have already implemented medicine reconciliation as a service, 
and there is a need for more studies to show if MR is a good enough initiative to reduce the 
amount of errors and justify the additional resources invested in this. Holmestad et al.’s study 
from 2015 did not find a significant difference in errors between lists with MR vs. lists 
without(117) and inadequate implementation and training of the pharmacists to conduct MR 
might be a factor to why there was found no difference. Nevertheless, future studies of the 
MR process in hospital settings should aim to measure the effects that is relevant to the 
patient, i.e. adverse drug events, life quality or QALY (Quality-adjusted life years) which is 
what the British NHS uses to accept studies. Such outcome measures would be more 
appropriate to see if MR is a suitable intervention.  Studies counting DRPs or errors does not 
measure the services advantages’, or what benefits there actually is to the patient. We cannot 
assume better clinical outcomes for the patients in reducing errors or discrepancies in the 
medicine lists. Research should also aim to measure the cost-benefit of the MR process to 
identify if it is an appropriate and economic method to spend health resources.  
Since our study shows that there is no evidence on an impact of electronic journal systems 
and records to disprove the need for human intervention, there will still be a need to find 














Our study shows that there was no evidence of the impact of electronical journal systems on 
the medicine lists to negate the need for human intervention, and the existing process of care 
transition communication at the healthcare interface is not optimum. Evidence to support the 
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Appendix 1 Integrated Medicines Management Procedure 
PROSEDYRE 
Legemiddelsamstemming etter IMM-metodikken 
Versjonsnr.: {_UIVersionString}  
Dok.status: {_ModerationStatus} 
 
Prosessområde: Selge og levere legemidler, apotekvarer og farmasifaglige tjenester 
Prosess(er): Utfør farmasifaglige tjenester 
Dokumenteier: Fagsjef AFT 
Gjelder fra dato: 01.03.2015 
 
Prosedyre utarbeidet av: Rykken, Sidsel 11.12.2014 
Prosedyre godkjent av: [Godkjent av] [Godkjent dato] 
 




Kvalitetssikring av pasienters legemiddelliste ved innleggelse i sykehus. 
 
2. Definisjoner 
Klinisk farmasøyt: farmasøyt som har fått tilstrekkelig opplæring til å gjennomføre kliniske, 
pasientrettede tjenester. 
Aktuell legemiddelliste/legemiddelintervju: en metode for å oppnå en oppdatert legemiddelliste 
som samstemmes med pasientens legemiddelbehandling i øyeblikket. Ved legemiddelintervju er 
det også mulig å identifisere pasientenes evner og potensielle problemer relatert til compliance, 
kunnskap og håndtering av legemidler. 
 
3. Omfang og avgrensninger 
Berører alle kliniske farmasøyter ved utføring av legemiddelsamstemming ved 
legemiddelintervju eller aktuell liste. 
 
Legemiddelsamstemming utføres for å oppnå en så nøyaktig oversikt som mulig over 
legemidlene pasienten bruker. Ved skifte av omsorgsnivå er det risiko for feil og mangler i 
legemiddellisten og det er derfor viktig at samstemming utføres ved overgangene. 
 
4. Ansvar 
Avdelingsleder for AFT har ansvar for at medarbeidere har fått tilstrekkelig opplæring før 
legemiddelsamstemming kan gjennomføres. 
Klinisk farmasøyt har ansvar for gjennomføring av legemiddelsamstemming i henhold til denne 
prosedyren. 
 
5.  Beskrivelse / utførelse 
 
Generelt om føring av skjemaet 
Understreket tekst angir hvordan skjemaet fylles ut. 
 
Avhaking/avkryssing brukes gjennomgående i hele prosedyren som følgende:  
 Hake () betyr: Pasient er spurt, men ingen problemer funnet  
 Kryss (x) betyr: Pasient er spurt og problem er funnet/kommentar gitt (husk 
dokumentasjon av problem/kommentar) 
 Åpen rubrikk betyr: Pasient er ikke spurt 
 
Se vedlegg 1 og vedlegg 2. 
 
Forberedelse 
Hent ut informasjon om pasientens sykdomshistorie fra pasientjournalen og opplysninger om 
ordinerte legemidler fra kurven.  
 
Fyll ut avdeling, rom og sengenummer, pasientens navn og fødselsdato. Dokumenter også om 
pasienten håndterer legemidlene sine selv eller ikke. Hvis pasienten mottar legemidlene som 
multidose krysses av for dette og versjonsnummer dokumenteres. 
 
Dokumenter på skjemaet under ”Annen info fra samtalen” (til venstre) informasjon som du 
henter fra journalen angående innleggelses årsak og tidligere diagnoser. I høyre hjørne av 
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samme rubrikk dokumenteres sosial informasjon som for eksempel boform, livssituasjon, hørsel 
og annet som kan være av nytte for gjennomføring av intervjuet. Eventuelt kan disse 
opplysningene dokumenteres i skjema for legemiddelgjennomgang og medbringes ved 
intervjuet.  
 
Fyll ut informasjon fra kurven inkludert legemiddelnavn, -form og styrke samt dosering. (Se 
vedlegg 1 for doseringskoder) Dokumenter alle legemidler som pasienten har hatt på avdelingen 
siden innleggelse, med unntak av de legemidlene som ble startet og seponert i tiden mellom 
innleggelse og intervjuet (f.eks. engangsdoser). 
 
De legemidlene som pasienten stod på ved innleggelse markeres med en pil (→) i kolonnen ”Dat 
IN”. For legemidler som er startet under innleggelsen dokumenteres dato for oppstart i ”Dat 
IN”. Legemidler som har blitt nullet eller seponert merkes med henholdsvis 0 eller S i kolonnen 
”Dosering”, tidligere dosering noteres i kommentarfeltet i parentes og dato for seponering 
skrives i kolonnen ”Dat UT”. 
 
Utføring av legemiddelintervju med pasienten 
For pasienter som håndterer egne legemidler utføres et legemiddelintervju. Ved behov kan man 
innhente supplerende opplysninger fra hjemmesykepleien, apoteket, fastlegen og/eller 
pårørende. Helsepersonell som yter helsehjelp har ikke plikt til å be om pasientens samtykke for 
å hente ut informasjon, men man bør ha grunn til å tro at pasienten ønsker opplysningene 
videreformidlet. Pasienten kan i enkelte tilfeller informeres før helseopplysningene utveksles av 
hensyn til personvernet1,2. 
 
Se egen arbeidsbeskrivelse for utføring av legemiddelintervju. 
 
Informasjon som pasienten gir under intervjuet omkring legemiddelbruken dokumenteres i 
kolonnen under ”Dosering”. Marker at informasjonen er gitt av pasienten ved å sette en ”P” i 
første underkolonne. Utfyllende informasjon kan skrives i kommentarfeltet eller i rubrikken 
”Annen info fra samtalen”. 
 
Informasjon innhentet fra andre kilder dokumenteres i de andre underkolonnene under 
”Dosering”. Marker hvor informasjonen kommer fra: P (pasient), PR (Pårørende), F (fastlege), M 
(multidose) FP (FarmaPro), KHT (kommunehelsetjenesten), J (EPJ – sykehusjournal). Dersom 
pårørende blir brukt som informasjonskilde noteres pårørendes relasjon til pasienten.  
 
Når man har behov for å hente ut legemiddelinformasjon fra andre apotek, må pasienten 
etterspørres hvilket apotek han/hun bruker oftest. Noter navnet på apoteket i skjemaet nederst 
til venstre. Ved bruk av utskrift fra FarmaPro kan man notere dato for siste uthenting og 
mengde. 
 
Etter utført intervju samstemmes sykehusets legemiddelkurve opp imot pasientens 
legemiddelliste og eventuell utfyllende informasjon. Ved uoverensstemmelser i legemiddelnavn, 
styrker og doseringer dokumenteres dette i de respektive kolonnene, eventuelt i 
kommentarfeltet. (Se siste avsnitt omkring uoverensstemmelser) 
 
Signer og dater for utført legemiddelintervjuet i rubrikken ”Utført”. Kryss av for 
legemiddelintervju (LMI) utført i boksen ”LMI” øverst i venstre hjørne. Det krysses av for LMI så 
lenge man har snakket med pasienten selv vedrørende hans/hennes legemidler og håndtering 
av disse (eventuelt snakket med pårørende).  
 
Utføring av aktuell legemiddelliste 
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For pasienter som får hjelp til legemiddeladministrasjon av for eksempel hjemmesykepleier eller 
som bor på sykehjem, kontrolleres legemiddelkurven opp mot aktuell liste fra henholdsvis 
hjemmesykepleie, fastlege, apotek/multidoseapotek eller sykehjem. Be om å få listen faxet til 
avdelingen og legg en kopi i pasientens kurvemappe. Hvis det ikke er tilgang på fax, kan man 
utføre et intervju per telefon med sykepleier/fastlege. Hvis pasienten får hjelp av pårørende kan 
man intervjue denne så lenge pasienten tillater det. Husk å notere pårørendes relasjon til 
pasienten. 
 
Fyll ut dosering av legemidlene i underrubrikken under ”Dosering” og marker underkolonnen i 
henhold til hvor informasjonen kommer fra (se over for forkortelser). Kontroller den innhentede 
aktuelle legemiddellisten opp mot legemiddelkurven på avdelingen. Ved uoverensstemmelser i 
legemiddelnavn, styrker og doseringer dokumenteres dette i de respektive kolonnene, eventuelt 
i kommentarfeltet. (Se siste avsnitt omkring uoverensstemmelser) Signer og dater for utført 
aktuell liste og kryss av i boksen ”AL” øverst til høyre. 
 
Uoverensstemmelser 
Ved uoverensstemmelser (avvik) mellom legemiddelkurven og informasjon fra pasient eller 
aktuell liste markeres avviket.  
 
Uoverensstemmelser diskuteres med lege snarest og dokumenteres i skjema for 
legemiddelgjennomgang i kolonnen ”Avvik i legemiddelintervju/aktuell liste”. Oppdaterte 




1. Helsepersonelloven: Lov 2. juli 1999 nr 64, §22 Samtykke til å gi informasjon; §25 
Opplysninger til samarbeidende helsepersonell; §45 Utlevering og tilgang til journal og 
journalopplysninger. 
 
2. Helsepersonells taushetsplikt. Vern av pasientens integritet i muntlig kommunikasjon mellom 
pasient og helsepersonell. Rundskriv, Helsedirektoratet IS-6/2010 
 
7. Vedlegg 
Vedlegg 1 Legemiddelintervju - Legemiddelsamstemming 
Vedlegg 2 Dokumentasjonsskjema - Legemiddelsamstemming 
 











Appendix 2 Standardised form for completion of medicine reconciliation 
 
Avd Seng Navn Fødselsdato Utført (dato, sign) 
Aktuell legemiddelliste (etter LMkurve)                Frikort   Ja     Nei Samstemt LMliste Håndtere 
LM selv# 
Pasient håndterer LM selv?                Ja                Nei 
Multidose?       Nei       Ja, versjon 
______ 
Dosering* 
Problem (x)  
Ikke p. () 
Dat 
IN 
Legemiddel, beredningsform, styrke Dosering Kommentar 
Dat 
UT 
   Ind EL 
          
          
          
          
          
          
          
          
          
          
          
          
          
          
          
          
*Info fra: pasient (P), pårørende (PR), fastlege (F), kommunehelsetjeneste (KHT), multidose (M), FarmaPro (FP), sykehusjournal - EPJ (J) #Ind: Indikasjon; EL: etterlevelse 
Annen info fra samtalen  







Tar du noen andre legemiddel?  smerte  hjerte  mage  diabetes  skjelett  søvn/uro  nedstemthet  allergi  
 øye-/øredråper/nesespray  inhalasjonslm  injeksjoner  krem/plaster  stikkpiller/vagitorier  prevensjon  
prostata/potens  andre reseptfrie lm  naturlm/helsekost  lm som tas per uke/mnd/år  avsluttet lm i forbindelse med 
innleggelse 










Appendix 3 Consent form for patients (Norwegian) 
FORESPØRSEL OM DELTAKELSE I FORSKNINGSPROSJEKTET 
Kan ELEKTRONISKE JOURNALSYSTEMER 
ERSTATTE MENNESKELIG INTERVENSJON VED 
LEGEMIDDELSAMSTEMMING? 
Dette er et spørsmål til deg om å delta i en forskningsprosjekt for å undersøke om det finnes 
uoverensstemmelser mellom informasjon som blir hentet fra elektroniske journaler og systemer med 
informasjon som blir hentet på legemiddelintervju. Kvalitetssikring av en pasient sitt reelle 
legemiddelbruk er av stor betydning for pasientsikkerheten ved videre behandling både under og 
etter sykehusopphold og det er derfor avgjørende for helsepersonell på sykehuset for å få en korrekt 
oversikt over legemiddelbruken tidlig i pasientforløpet. Studien tar plass ved kardiologisk avdeling på 
Haukeland Universitetssykehus, og studien sikter på å ta med pasienter som er innlagt her og har fått 
utskrevet medisiner før og under innleggelse. Studiet er en del av en masteroppgave i Integrert 
Masterprogram i Farmasi ved Universitetet i Bergen. 
 
HVA INNEBÆRER PROSJEKTET? 
I prosjektet vil vi innhente og registrere opplysninger om deg. Fra sykehusets elektroniske 
journalsystem og legemiddelkurver vil vi innhente informasjon om alder, kjønn, diagnose, 
informasjon fra tidligere notater eller epikriser som kan være relevant for din medisinbruk og 
eventuelt medisinliste fra poliklinikker. Fra legemiddelintervjuet vil det bli innhentet informasjon om 
legemidlene og legemiddelbruken. Disse opplysningene vil deretter bli sammenlignet med din 
informasjon fra Reseptformidleren og Kjernejournal. 
Rekrutterte deltakere vil få en legemiddelsamstemning som er prosessen med å samle og verifisere 
en korrekt liste av deltakerens legemidler og medisinbruk, inkludert navn, dosering og frekvens fra 
flere forskjellige kilder, og deretter sammenligne denne informasjon med utskrevne resepter og 
medisinene som deltakeren faktisk bruker ved å foreta et legemiddelintervju. Informasjonen som blir 
hentet vil bli dokumentert og deretter vurdert av 2 farmasøyter og 2 leger. Deltakelse i dette 
prosjektet vil ikke avvike fra ordinær behandling annet enn at deltakeren går gjennom et 
legemiddelintervju. Legemiddelintervjuet vil ta cirka 10-15 minutter. 
MULIGE FORDELER OG ULEMPER 
Dette er en studie som har som formål å bidra til økt kvalitet i legemiddelbehandlingen uten å 
inkludere belastende kliniske undersøkelser. Evaluering og forbedring av den enkelte pasients 
legemiddelbehandling har fordeler som bedre og riktigere legemiddelbruk. Dette forhindrer at du 
ikke får administrert noe de har fått før, det forhindrer legemiddelrelaterte problemer og fører 




FRIVILLIG DELTAKELSE OG MULIGHET FOR Å TREKKE SITT SAMTYKKE  
Det er frivillig å delta i prosjektet. Dersom du ønsker å delta, undertegner du samtykkeerklæringen 
på siste side. Du kan når som helst og uten å oppgi noen grunn trekke ditt samtykke. Dette vil ikke få 
konsekvenser for din videre behandling. Dersom du trekker deg fra prosjektet, kan du kreve å få 
slettet innsamlede prøver og opplysninger, med mindre opplysningene allerede er inngått i analyser 
eller brukt i vitenskapelige publikasjoner. Dersom du senere ønsker å trekke deg eller har spørsmål til 
prosjektet, kan du kontakte André Luong, på +47 941 69 492 eller andrehuy.92@gmail.com 
 
HVA SKJER MED INFORMASJONEN OM DEG?  
Informasjonen som registreres om deg skal kun brukes slik som beskrevet i hensikten med studien. 
Du har rett til innsyn i hvilke opplysninger som er registrert om deg og rett til å få korrigert eventuelle 
feil i de opplysningene som er registrert. 
Alle opplysningene vil bli behandlet uten navn og fødselsnummer eller andre direkte gjenkjennende 
opplysninger. En kode knytter deg til dine opplysninger gjennom en navneliste 
Prosjektleder har ansvar for den daglige driften av forskningsprosjektet og at opplysninger om deg 
blir behandlet på en sikker måte.  Informasjon om deg vil bli anonymisert eller slettet etter 
prosjektslutt.  
 
SAMTYKKE TIL DELTAKELSE I PROSJEKTET 
 
JEG ER VILLIG TIL Å DELTA I PROSJEKTET  
 




 Deltakers navn med trykte bokstaver 
 
 
Jeg bekrefter å ha gitt informasjon om prosjektet  
 




 Rolle i prosjektet 
 
 
